The invention relates to benzoxazepin compounds of Formula I including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N； Z 2 is CR 2 or N； Z 3 is CR 3 or N； Z 4 is CR 4 or N； and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.
